fiveprime.com
Pipeline | Five Prime Therapeutics
http://www.fiveprime.com/pipeline
Five Prime is pursuing discovery and clinical development of its product candidates both independently and in collaboration with pharmaceutical partners. We are focused primarily on therapies for cancer and have three drug candidates in active human clinical trials. We are also focusing our earlier stage research efforts on immuno-oncology. Hane Chow, Inc.
fiveprime.com
Protein Library | More than 5,600 Human Proteins | Five Prime Therapeutics
http://www.fiveprime.com/platform/protein-library
Our library is derived from more than 100 distinct human tissues, and comprises more than 5,700 human proteins. Hane Chow, Inc.
fiveprime.com
Board of Directors | Five Prime Therapeutics
http://www.fiveprime.com/company/board-of-directors
Lewis T. Rusty Williams, M.D., Ph.D. Founder, President, CEO and Chairman of the Board. Franklin M. Berger, CFA. Fred E. Cohen, M.D., D. Phil. Kapil Dhingra, M.B.B.S. Sheila Gujrathi, M.D. Peder K. Jensen, M.D. Senior Vice President and Chief Business Officer. Mark D. McDade. William R. Ringo. Hane Chow, Inc.
fiveprime.com
Management | Five Prime Therapeutics
http://www.fiveprime.com/company/management
Lewis T. Rusty Williams, M.D., Ph.D. Founder, President and CEO. Executive Vice President and Chief Business Officer. Executive Vice President, General Counsel and Secretary. Kevin Baker, Ph.D. Senior Vice President, Development Sciences. Senior Vice President and Chief Financial Officer. Senior Vice President, Human Resources. Robert Sikorski, M.D., Ph.D. Senior Vice President and Chief Medical Officer. Luis Borges, Ph.D. Vice President, Immuno-Oncology Research. Hane Chow, Inc.
fiveprime.com
Company Information | Protein Therapeutics | Five Prime Therapeutics
http://www.fiveprime.com/company
Five Prime is a leader in the discovery and development of innovative protein therapeutics. We have developed a library of more than 5,700 human extracellular proteins, which we believe represent substantially all of the body’s medically important targets for protein therapeutics. Our drug discovery platform has also made us a sought-after discovery and development partner. To date we entered into multiple collaborations with partners, including Bristol-Myers Squibb, GlaxoSmithKline and UCB Pharma.
fiveprime.com
FPA144 | Gastric Cancer | Five Prime Therapeutics
http://www.fiveprime.com/pipeline/fpa144
FPA144 is an anti-FGF receptor 2b (FGFR2b) humanized monoclonal antibody in clinical development as a targeted immune therapy for tumors that over-express FGFR2b, as determined by a proprietary immunohistochemistry (IHC) diagnostic assay. Gene amplification (as identified by FISH) is found in a number of tumors, including in approximately 5% of gastric cancer patients, and is associated with poor prognosis. FPA144 is designed to block tumor growth through two distinct mechanisms:. 2 Partial Responses (1 ...
fiveprime.com
Recent Press Releases | Media Relations | Five Prime Therapeutics
http://www.fiveprime.com/news-media
Five Prime Announces Second Quarter 2016 Results and Provides Business Update. August 4, 2016. Five Prime Therapeutics to Announce Second Quarter 2016 Financial Results and Host Conference Call on August 4. July 18, 2016. GSK Exclusively Licenses Intellectual Property for Respiratory Disease Target Identified Using Five Prime's Proprietary Protein Discovery Platform. July 14, 2016. For more information please contact Five Prime Media Relations at:. South San Francisco, CA 94080. Hane Chow, Inc.
fiveprime.com
Platform | Proprietary Library | Proprietary Screens | Five Prime Therapeutics
http://www.fiveprime.com/platform
Five Prime has successfully developed a platform to improve the traditionally difficult and slow process of discovering new protein therapeutics. The platform is based on two components:. A proprietary library of more than 5,700 human extracellular proteins that we believe is the most comprehensive collection of fully functional extracellular proteins and is an abundant source of medically relevant novel targets for protein therapeutics; and. Hane Chow, Inc.
fiveprime.com
Cell-Based Screens | RIPPS® | Receptor-Ligand Matching | Five Prime Therapeutics
http://www.fiveprime.com/platform/proprietary-screens
Medically important proteins can take many forms. They can be ligands that are being overproduced by genetically damaged cells and generating uncontrolled cell division. They can stimulate an unmediated, aggressive attack by the immune system that causes excessive inflammation. They can be receptor proteins that are being over-expressed and catalyzing a dangerous surplus of regulatory proteins inside the cell. Rapid In Vivo Protein Production System (RIPPS. Hane Chow, Inc.
fiveprime.com
FP-1039 | GSK 3052230 | Multiple Solid Tumors | Five Prime Therapeutics
http://www.fiveprime.com/pipeline/fp-1039
FP-1039 is a ligand trap that is designed to selectively intervene in fibroblast growth factor (FGF) signaling. FGFs are a family of 22 related extracellular proteins called ligands that normally regulate cell proliferation and survival in humans. They act by binding to and activating FGF receptors (FGFRs), which are cell surface proteins that transmit growth signals to cells. Certain FGFs promote growth of multiple solid tumors by binding and activating FGFRs. On March 9, 2016, GSK notified Five Prime t...
SOCIAL ENGAGEMENT